Top

Supportive Care in Cancer

Published in:

01-09-2019 | Gingival Diseases | Original Article

Prevalence of oral side effects of chemotherapy and its relationship with periodontal risk: a cross sectional study

Authors: B. García-Chías, E. Figuero, B. Castelo-Fernández, J. L. Cebrián-Carretero, R. Cerero-Lapiedra

Published in: Supportive Care in Cancer | Issue 9/2019

Abstract

Purpose

To determine the prevalence of professionally reported oral side effects of chemotherapy and the self-reported oral side effects and whether both prevalences could be related to the periodontal risk of the patients.

Methods

A cross-sectional study with patients undergoing chemotherapy treatment was carried out. Demographic, oral hygiene habits, and cancer-related data were collected while the patient was receiving the chemotherapy infusion. Patient’s oral status, measured according to the oral-assessment guide for patients in hospital environments, patient-related outcomes (PROMs), measured by a visual analogue scale, and patient’s periodontal risk were analyzed using validated questionnaires. Data was reported in means and standard deviations (SD) in quantitative variables and in counts, prevalence, and 95% confidence intervals (CI) in qualitative variables. ANOVA test and chi-squared tests were used to compare oral side effects among different periodontal risk groups.

Results

Three hundred sixty-nine patients were included in the study. The prevalence of professionally reported oral side effects was 86.99% (95% confidence interval CI 83.54%; 90.44%). The prevalence of self-reported oral side effects was 89.70% (95% CI 86.59; 92.82). The most common oral side effects were xerostomia (73.4%), dysgeusia (61.8%), and dry lips (54.2%). More oral alterations were found in patients with worse periodontal risk (p < 0.001).

Conclusions

The prevalence of oral side effects (professional or self-reported) is higher than 85% in patients undergoing chemotherapy. This prevalence increases as the risk of developing periodontal disease does.

Available only for authorised users

Ruiz-Esquide G, Nervi B, Vargas A, Maíz A (2011) Treatment and prevention of cancer treatment related oral mucositis. Rev Med Chil 139(3):373–381. https://doi.org/10.4067/s0034-98872011000300015 CrossRefPubMed

Wong HM (2014) Oral complications and management strategies for patients undergoing cancer therapy. Sci World J 2014. https://doi.org/10.1155/2014/581795

Watters A, Epstein J, Agulnik M (2011) Oral complications of targeted cancer therapies: a narrative literature review. Oral Oncol 47(6):441–448. https://doi.org/10.1016/j.oraloncology.2011.03.028 CrossRefPubMed

López BC, Esteve CG, Pérez MGS (2011) Dental treatment considerations in the chemotherapy patient. J Clin Exp Dent 3(1):31–42. https://doi.org/10.4317/jced.3.e31 CrossRef

Hsu H-C, Tsai S-Y, Wu S-L, Jeang S-R, Ho M-Y, Liou W-S, Chiang A-J, Chang T-H (2017) Longitudinal perceptions of the side effects of chemotherapy in patients with gynecological cancer. Support Care Cancer 25(11):3457–3464. https://doi.org/10.1007/s00520-017-3768-7 CrossRefPubMed

López BC (2014) Oral toxicity produced by chemotherapy: a systematic review. J Clin Exp Dent 6(1):81–90. https://doi.org/10.4317/jced.51337 CrossRef

Sonis S, Kunz A (1988) Impact of improved dental services on the frequency of oral complications of cancer therapy for patients with non-head-and-neck malignancies. Oral Surg Oral Med Oral Pathol 65(1):19–22. https://doi.org/10.1016/0030-4220(88)90184-3 CrossRefPubMed

Sweeney M, Bagg J, Baxter W, Aitchison T (1998) Oral disease in terminally ill cancer patients with xerostomia. Oral Oncol 34(2):123–126. https://doi.org/10.1016/s1368-8375(97)00076-6 CrossRefPubMed

Fayle SA, Curzon ME (1991) Oral complications in pediatric oncology patients. Pediatr Dent 13(5):289–295PubMed

10.

Cheng KKF (2007) Oral mucositis, dysfunction, and distress in patients undergoing cancer therapy. J Clin Nurs 16(11):2114–2121. https://doi.org/10.1111/j.1365-2702.2006.01618.x CrossRefPubMed

11.

Dodd M, Facione N, Dibble S, MacPhail L (1996) Comparison of methods to determine the prevalence and nature of oral mucositis. Cancer Pract 4(6):312–318PubMed

12.

Epstein JB, Thariat J, Bensadoun RJ, Barasch A, Murphy BA, Kolnick L, Popplewell L, Maghami E (2012) Oral complications of cancer and cancer therapy. CA Cancer J Clin 62(6):400–422. https://doi.org/10.3322/caac.21157 CrossRefPubMed

13.

Sonis ST, Lieberman A, Sonis AL (1978) Oral complications in patients receiving treatment for malignancies other than of the head and neck. J Am Dent Assoc 97(3):468–472. https://doi.org/10.14219/jada.archive.1978.0304 CrossRefPubMed

14.

Andersson P, Persson L, Hallberg IR, Renvert S (1999) Testing an oral assessment guide during chemotherapy treatment in a Swedish care setting: a pilot study. J Clin Nurs 8(2):150–158. https://doi.org/10.1046/j.1365-2702.1999.00237.x CrossRefPubMed

15.

Scully C, Epstein JB (1996) Oral health care for the cancer patient. Eur J Cancer B Oral Oncol 32(5):281–292. https://doi.org/10.1016/0964-1955(96)00037-1 CrossRef

16.

Chan CW, Chang AM, Molassiotis A, Lee IY, Lee GC (2003) Oral complications in Chinese cancer patients undergoing chemotherapy. Support Care Cancer 11(1):48–55. https://doi.org/10.1007/s00520-002-0413-9 CrossRefPubMed

17.

Konwinska MD, Mehr K, Owecka M, Kulczyk T (2014) Oral health status in patients undergoing chemotherapy for lung cancer. Open J Dent Oral Med 2(1):17–21. https://doi.org/10.13189/ojdom.2014.020104 CrossRef

18.

Villafuerte KRV, Martinez CJH, Dantas FT, Carrara HHA, dos Reis FJC, Palioto DB (2018) The impact of chemotherapeutic treatment on the oral microbiota of cancer patients: a systematic review. Oral Surg Oral Med Oral Pathol 125:552–566CrossRef

19.

Lalla RV, Bowen J, Barasch A, Elting L, Epstein J, Keefe DM, McGuire DB, Migliorati C, Nicolatou-Galitis O, Peterson DE (2014) MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 120(10):1453–1461. https://doi.org/10.1002/cncr.28592 CrossRefPubMed

20.

Eilers J, Berger AM, Petersen M (1987) Development, testing, and application of the oral assessment guide. Oncol Nurs Forum 15(3):325–330

21.

Serrano JHD (2011) Evaluación de un cuestionario para la asignación del riesgo individual del individuo en el desarrollo de las enfermedades periodontales. Periodoncia y Osteointegración 21(2):133–142

22.

Gomes AOF, Junior AS, Noce CW, Ferreira M, Maiolino A, Torres SR (2018) The frequency of oral conditions detected in hematology inpatients. Hematol Transfus Cell Ther 40:240–244. https://doi.org/10.1016/j.htct.2018.02.006 CrossRefPubMedPubMedCentral

23.

Jobbins J, Bagg J, Finlay IG, Addy M, Newcombe R (1992) Oral and dental disease in terminally ill cancer patients. BMJ 304(6842):1612. https://doi.org/10.1136/bmj.304.6842.1612 CrossRefPubMedPubMedCentral

24.

Jensen SB, Pedersen AML, Vissink A, Andersen E, Brown CG, Davies AN, Dutilh J, Fulton JS, Jankovic L, Lopes NN (2010) A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life. Support Care Cancer 18(8):1039–1060. https://doi.org/10.1007/s00520-010-0827-8 CrossRefPubMed

25.

Mercadante S, Aielli F, Adile C, Ferrera P, Valle A, Fusco F, Caruselli A, Cartoni C, Massimo P, Masedu F (2015) Prevalence of oral mucositis, dry mouth, and dysphagia in advanced cancer patients. Support Care Cancer 23(11):3249–3255. https://doi.org/10.1007/s00520-015-2720-y CrossRefPubMed

26.

Ponticelli E, Clari M, Frigerio S, De Clemente A, Bergese I, Scavino E, Bernardini A, Sacerdote C (2017) Dysgeusia and health-related quality of life of cancer patients receiving chemotherapy: a cross-sectional study. Eur J Cancer Care 26 (2). doi:https://doi.org/10.1111/ecc.12633

27.

Bernhardson B-M, Tishelman C, Rutqvist LE (2008) Self-reported taste and smell changes during cancer chemotherapy. Support Care Cancer 16(3):275–283. https://doi.org/10.1007/s00520-007-0319-7 CrossRefPubMed

28.

Lockhart PB, Sonis ST (1981) Alterations in the oral mucosa caused by chemotherapeutic agents. J Dermatol Surg Oncol 7(12):1019–1025. https://doi.org/10.1111/j.1524-4725.1981.tb00208.x CrossRefPubMed

29.

Taichman LS, Van Poznak CH, Inglehart MR (2018) Oral health-related concerns, behavior, and communication with health care providers of patients with breast cancer: impact of different treatments. Spec Care Dentist 38(1):36–45. https://doi.org/10.1111/scd.12266 CrossRefPubMed

30.

Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, Bekele BN, Raber-Durlacher J, Donnelly JP, Rubenstein EB (2004) Perspectives on cancer therapy-induced mucosal injury. Cancer 100(S9):1995–2025. https://doi.org/10.1002/cncr.20162 CrossRefPubMed

31.

Fitzpatrick SG, Katz J (2010) The association between periodontal disease and cancer: a review of the literature. J Dent 38(2):83–95. https://doi.org/10.1016/j.jdent.2009.10.007 CrossRefPubMed

32.

Overholser C, Peterson DE, Williams LT, Schimpff SC (1982) Periodontal infection in patients with acute nonlymphocytic leukemia: prevalence of acute exacerbations. Arch Intern Med 142(3):551–554. https://doi.org/10.1001/archinte.1982.00340160131025 CrossRefPubMed

33.

Djuric M, Cakic S, Hadzi-Mihailovic M, Petrovic D, Jankovic L (2010) Oral status in patients receiving 5-fluorouracil for colorectal cancer. J BUON 15(3):475–479PubMed

34.

Jensen SB, Mouridsen HT, Bergmann OJ, Reibel J, Brunner N, Nauntofte B (2008) Oral mucosal lesions, microbial changes, and taste disturbances induced by adjuvant chemotherapy in breast cancer patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 106(2):217–226. https://doi.org/10.1016/j.tripleo.2008.04.003 CrossRefPubMed

35.

Mazzeo MA, Linares JA, Campos ML, Busamia BE, Dubersarsky C, Lavarda M, Jarchum G, Finkelberg AB (2009) Oral signs of intravenous chemotherapy with 5-Fluorouracil and Leucovorin calcium in colon cancer treatment. Med Oral Patol Oral Cir Bucal 14(3):E108–E113PubMed

Title: Prevalence of oral side effects of chemotherapy and its relationship with periodontal risk: a cross sectional study
Authors: B. García-Chías
E. Figuero
B. Castelo-Fernández
J. L. Cebrián-Carretero
R. Cerero-Lapiedra
Publication date: 01-09-2019
Publisher: Springer Berlin Heidelberg
Keywords: Gingival Diseases
Cytostatic Therapy
Published in: Supportive Care in Cancer / Issue 9/2019
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-019-4650-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 9/2019

Effect of acupressure on constipation in patients with advanced cancer

Physical activity and fitness among pediatric cancer survivors: a meta-analysis of observational studies

The association of socioeconomic status with quality of life in cancer patients over a 6-month period using individual growth models

Cognitive rehabilitation for cancer-related cognitive dysfunction: a systematic review

Are cancer helplines effective in supporting caregivers? A systematic review

Correction to: Human Development Index and its association with staff spiritual care provision: a Middle Eastern oncology study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer